Cardinal Health price target raised to $260 from $240 at BofA
BofA raised the firm’s price target on Cardinal Health (CAH) to $260 from $240 and keeps a Buy rating on the shares, citing relative upside to consensus estimates and strong…
Fiscal Year: July - June
Cardinal Health, Inc. (CAH), listed on the NYSE, has a market capitalization of $55.96B. As of Jul 03, 2026, the stock is trading at $238.94 per share@else an unavailable price , offering investors a clear view of its current market value. Cardinal Health, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 36.55, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Cardinal Health, Inc. also offers a dividend yield of 0.85%, making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Cardinal Health, Inc. (CAH). The fair value estimate will be displayed once sufficient analyst forecast data is collected.
The proprietary SS Score for Cardinal Health, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Cardinal Health, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Cardinal Health, Inc. is 12.76, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Cardinal Health, Inc. (CAH) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Cardinal Health, Inc. (CAH) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Cardinal Health, Inc. (CAH) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Cardinal Health, Inc.. To access the full SS Score, consider upgrading your subscription.
Cardinal Health, Inc. is a significant player in the industry sector, with a market capitalization of $55.96B and a competitive P/E ratio of 36.55. Investors should compare these metrics with industry peers to gauge whether Cardinal Health, Inc. is outperforming or underperforming within its sector.
BofA raised the firm’s price target on Cardinal Health (CAH) to $260 from $240 and keeps a Buy rating on the shares, citing relative upside to consensus estimates and strong…
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Compa...
JPMorgan analyst Lisa Gill lowered the firm’s price target on Cardinal Health (CAH) to $215 from $243 and keeps a Neutral rating on the shares.
Baird lowered the firm’s price target on Cardinal Health (CAH) to $248 from $257 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results…
TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $255 from $251 and keeps a Buy rating on the shares. The firm updated its model following quarterly…
Citi analyst Daniel Grosslight lowered the firm’s price target on Cardinal Health (CAH) to $245 from $249 and keeps a Buy rating on the shares.
BofA lowered the firm’s price target on Cardinal Health (CAH) to $240 from $260 to reflect lower peer multiples, while keeping a Buy rating on the shares. The firm notes…
Consensus $10.31. Raises FY26 adjusted free cash flow view to $3.3B-$3.7B from $3B-$3.5B. Lowers FY26 tax rate view to 19% from 21%-23%.
Cardinal Health raises its fiscal-year adjusted earnings guidance for the second time this year, helping investors look past mixed quarterly performance.
Cardinal Health once again raised its full-year outlook after logging higher-than-expected adjusted earnings in the third quarter.
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
Reports Q3 revenue $60.94B, consensus $62.24B. “An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business,” said Jason Hollar, CEO of Cardinal Health…
Revenue increased 11% to $60.9 billion GAAP 1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69 Non-GAAP operating earnings increased 18% to $956 million; non-G...
William Blair initiated coverage of Cardinal Health (CAH) with an Outperform rating. The firm says the company’s pharmaceutical distribution platform creates a “durable competitive moat” and supports ...
CNBC's Jim Cramer urged investors to look at parts of the market that have already been beaten down. He highlighted four stocks in the health-care sector as alternatives to high-flying technology and ...
Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, O...
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Cardinal Health (CAH) to $240 from $260 and keeps an Outperform rating on the shares. The firm made several…
Cardinal Health (CAH) announced a significant expansion of its Actinium-225 production capabilities at the company’s Center for Theranostics Advancement in Indianapolis, Indiana. The addition of a hig...
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.